Virus-based gene delivery systems

Clinical Pharmacokinetics

Volumn 41, Issue 12, 2002, Pages 901-911

  Mah, Cathryn ^a   Byrne, Barry J ^a   Flotte, Terence R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR PROTEIN; INTEGRIN; PROTEOHEPARAN SULFATE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BLOOD DISEASE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HERPES VIRUS; IMMUNOLOGY; LENTIVIRINAE; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; PARVOVIRUS; PRIORITY JOURNAL; RETROVIRUS; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 0036397852     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241120-00001     Document Type: Article

References (98)

1. Berns KI. Parvovirus replication. Microbiol Rev 1990; 54 (3): 316-29
2. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 1983; 45 (2): 555-64
3. Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med 2000; 6 (1): 17-27
4. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A 1984; 81 (20): 6466-70
5. Tratschin JD, West MH, Sandbank T, et al. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol 1984; 4 (10): 2072-81
6. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990; 87 (6): 2211-5
7. Kotin RM, Menninger JC, Ward DC, et al. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991; 10 (3): 831-4
8. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11 (13): 5071-8
9. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10 (12): 3941-50
10. Samulski RJ. Adeno-associated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev 1993; 3 (1): 74-80
11. Davidson BL, Stein CS, Heth JA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000; 97 (7): 3428-32
12. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996; 7 (17): 2101-12
13. Duan D, Yue Y, Yan Z, et al. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 2000; 6 (5): 595-8
14. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11 (5): 517-21
15. Kearns WG, Afione SA, Fulmer SB, et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in ah immortalized epithelial cell line. Gene Ther 1996; 3 (9): 748-55
16. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74 (8): 3852-8
17. Beck SE, Jones LA, Chesnut K, et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999; 73 (11): 9446-55
18. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72 (2): 1438-45
19. Qing K, Mah C, Hansen J, et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5 (1): 71-7
20. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5 (1): 78-82
21. Chiorini JA, Kim F, Yang L, et al. Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73 (2): 1309-19
22. Srivastava CH, Samulski RJ, Lu L, et al. Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proc Natl Acad Sci U S A 1989; 86 (20): 8078-82
23. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74 (18): 8635-47
24. Drapkin PT, O'Riordan CR, Yi SM, et al. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest 2000; 105 (5): 589-96
25. Bartlett JS, Kleinschmidt J, Boucher RC, et al. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 1999; 17 (2): 181-6
26. Flotte T, Carter B, Conrad C, et al. A phase I study of ah adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7 (9): 1145-59
27. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998; 351 (9117): 1702-3
28. Wagner JA, Moran ML, Messner AH, et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 1998; 9 (6): 889-909
29. Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109 (2 Pt 1): 266-74
30. Virella-Lowell I, Poirier A, Chesnut KA, et al. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 2000; 7 (20): I783-9
31. Kay MA, Manno CS, Ragni MV. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24 (3): 257-61
32. Yan Z, Zhang Y, Duan D, et al. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 2000; 97 (12): 6716-21
33. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333 (13): 823-31
34. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8 (1): 42-51
35. Morral N, Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9 (18): 2709-16
36. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18 (2): 180-3
37. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998; 72 (1): 415-9
38. Hidaka C, Milano E, Leopold PL, et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 1999; 103 (4): 579-87
39. Bouri K, Feero WG, Myerburg MM, et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999; 10 (10): 1633-40
40. Gonzalez R, Vereecque R, Wickham TJ, et al. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Ther 1999; 6 (3): 314-20
41. Wickham TJ, Tzeng E, Shears II LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71 (11): 8221-9
42. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adeno-virus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70 (10): 6831-8
43. Wickham TJ, Haskard D, Segal D, et al. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol Immunother 1997; 45 (3-4): 149-51
44. Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol 1997; 71 (10): 7663-9
45. Miller AD, Jolly DJ, Friedmann T, et al. A transmissible retrovirus expressing human hypoxanthine phosphoribosyl-transferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci U S A 1983; 80 (15): 4709-13
46. Miller AD, Ong ES, Rosenfeld MG, et al. Infectious and selectable retrovirus containing an inducible rat growth hormone minigene. Science 1984; 225 (4666): 993-8
47. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33 (1): 153-9
48. Cepko CL, Roberts BE, Mulligan RC. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 1984; 37 (3): 1053-62
49. Cone RD, Mulligan RC. High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range. Proc Natl Acad Sci U S A 1984; 81 (20): 6349-53
50. Williams DA, Orkin SH, Mulligan RC. Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo. Proc Natl Acad Sci U S A 1986; 83 (8): 2566-70
51. Palmer TD, Hock RA, Osborne WR, et al. Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human. Proc Natl Acad Sci U S A 1987; 84 (4): 1055-9
52. Ramsey WJ, Mullen CA, Blaese RM. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency [abstract]. Leukemia 1995; 9 Suppl. 1:S70
53. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10 (8): 4239-42
54. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A 1991; 88 (11): 4626-30
55. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6 (8): 2895-902
56. Miller AD. Retrovirus packaging cells. Hum Gene Ther 1990; 1 (1): 5-14
57. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272 (5259): 263-7
58. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4 (3): 354-7
59. Kafri T, Blomer U, Peterson DA, et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17 (3): 314-7
60. Miyoshi H, Smith KA, Mosier DE, et al. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283 (5402): 682-6
61. Kafri T, van Praag H, Ouyang L, et al. A packaging cell line for lentivirus vectors. J Virol 1999; 73 (1): 576-84
62. Miyoshi H, Blomer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol 1998; 72 (10): 8150-7
63. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30 (1): 295-304
64. Spaete RR, Frenkel N. The herpes simplex virus amplicon: analyses of cis-acting replication functions. Proc Natl Acad Sci U S A 1985; 82 (3): 694-8
65. Geller AI, Yu L, Wang Y, et al. Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Exp Neurol 1997; 144 (1): 98-102
66. Kwong AD, Frenkel N. Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eucaryotic DNA sequences. J Virol 1984; 51 (3): 595-603
67. Geller AI, Keyomarsi K, Bryan J, et al. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci U S A 1990; 87 (22): 8950-4
68. Glorioso JC, Goins WF, DeLuca N, et al. Development of herpes simplex virus as a gene transfer vector for the nervous system [abstract]. Gene Ther 1994; 1 Suppl. 1: S39
69. Fink DJ, Ramakrishnan R, Marconi P, et al. Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system. Clin Neurosci 1995; 3 (5): 284-91
70. Marconi P, Krisky D, Oligino T, et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A 1996; 93 (21): 11319-20
71. Glorioso JC, Goins WF, Schmidt MC, et al. Engineering herpes simplex virus vectors for human gene therapy. Adv Pharmacol 1997; 40: 103-36
72. Rooney JF, Wohlenberg C, Cremer KJ, et al. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 1988; 62 (5): 1530-4
73. Tsukamoto H, Wells D, Brown S, et al. Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice. Gene Ther 1999; 6 (7): 1331-5
74. Nakanishi M, Mizuguchia H, Ashihara K, et al. Gene transfer vectors based on Sendai virus. J Control Release 1998; 54 (1): 61-8
75. Nakanishi M, Mizuguchi H, Ashihara K, et al. Gene delivery systems using the Sendai virus. Mol Membr Biol 1999; 16 (1): 123-7
76. Herweijer H, Latendresse JS, Williams P, et al. A plasmid-based self-amplifying Sindbis virus vector. Hum Gene Ther 1995; 6 (9): 1161-7
77. Berglund P, Sjoberg M, Garoff H, et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Bio/technology 1993; 11 (8): 916-20
78. Caplen NJ, Higginbotham JN, Scheel JR, et al. Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther 1999; 6 (3): 454-9
79. Fisher KJ, Kelley WM, Burda JF, et al. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7 (17): 2079-87
80. Lohr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357 (9268): 1591-2
81. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994; 56 (3): 283-94
82. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5 (3): 309-13
83. Negishi Y, Kudo A, Obinata A. et al. Multipotency of abone marrow stromal cell line, TBR31-2, established from ts-SV40 T antigen gene transgenic mice. Biochem Biophys Res Commun 2000; 268 (2): 450-5
84. Prockop DJ. Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 1997; 276 (5309): 71-4
85. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284 (5411): 143-7
86. Pittenger MF, Mosca JD, McIntosh KR. Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. Curr Top Microbiol Immunol 2000; 251: 3-11
87. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte pheotype in the adult murine heart. Circulation 2002; 105(1): 93-8
88. Fukuda K. Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering. Artif Organs 2001; 25 (3): 187-93
89. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12 (8): 861-70
90. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70 (11): 7498-509
91. Mah C, Fraites TJ Jr, Zolotukhim I, et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 2002; 6 (1): 106-12
92. Weiss DJ, Strandjord TP, Liggitt D, et al. Perflubron enhances adenovirus-mediated gene expression in lungs of transgenic mice with chronic alveolar filling. Hum Gene Ther 1999; 10 (14): 2287-93
93. Weiss DJ, Strandjord TP, Jackson JC, et al. Perfluorochemical liquid-enhanced adenoviral vector distribution and expression in lungs of spontaneously breathing rodents. Exp Lung Res 1999; 25 (4): 317-33
94. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000; 7 (3): 232-40
95. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 2000; 97 (2): 793-8
96. Svensson EC, Marshall DJ, Woodard K, et al. Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999; 99 (2): 201-5
97. Hajjar RJ, Schmidt U, Matsui T, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A 1998; 95 (9): 5251-6
98. Lathi KG, Vale PR, Losordo DW, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 2001; 92 (1): 19-25